Literature DB >> 12177620

Constitutive activation of Jak/STAT proteins in Epstein-Barr virus-infected B-cell lines from patients with posttransplant lymphoproliferative disorder.

Ronald R Nepomuceno1, Andrew L Snow, P Robert Beatty, Sheri M Krams, Olivia M Martinez.   

Abstract

BACKGROUND: Posttransplant lymphoproliferative disease (PTLD) is a major complication after bone marrow and solid organ transplantation. The disease encompasses a spectrum of abnormal, Epstein-Barr virus (EBV)-associated B-cell proliferations. We have previously shown that EBV-infected, spontaneous lymphoblastoid cell lines (SLCL) derived from PTLD patients require autocrine interleukin (IL)-10 to proliferate. To determine if cytokine signal transduction is involved in the autonomous growth of the SLCL, the activation states of the Jak/STAT signaling pathway proteins were analyzed in three different SLCL, termed JB7, MF4, and VB4.
METHODS: The tyrosine phosphorylation (P-tyr) states of the Janus kinases (Jaks) and signal transducers and activators of transcription (STAT) proteins were examined by immunoprecipitation and immunoblot. Activated STAT dimer formation was determined by electromobility shift assays.
RESULTS: All three SLCL, but not the Daudi Burkitt's lymphoma B-cell line, expressed the four known Jak kinases constitutively tyrosine phosphorylated, with particularly high levels of P-tyr Jak1 in the JB7 line. STAT1 and STAT3, but not STAT2 or STAT5, are also constitutively activated in all SLCL. The ability of the activated STAT proteins to form DNA-binding dimers was confirmed by electromobility shift assay. The SLCL, but not the Daudi line, express activated STAT complexes composed of STAT1 and STAT3. Another EBV-infected B-cell line, isolated from a lymph node biopsy after kidney transplantation, is phenotypically similar to the other SLCL in both surface antigen and activated STAT1 and STAT3 expression.
CONCLUSION: These data support the presence of a constitutively active autocrine signaling pathway consistent with IL-10 in the SLCL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12177620     DOI: 10.1097/00007890-200208150-00017

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  17 in total

1.  B lymphocytes from patients with a hypomorphic mutation in STAT3 resist Epstein-Barr virus-driven cell proliferation.

Authors:  Siva Koganti; Amanda de la Paz; Alexandra F Freeman; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

2.  STAT3 interrupts ATR-Chk1 signaling to allow oncovirus-mediated cell proliferation.

Authors:  Siva Koganti; Joyce Hui-Yuen; Shane McAllister; Benjamin Gardner; Friedrich Grasser; Umaimainthan Palendira; Stuart G Tangye; Alexandra F Freeman; Sumita Bhaduri-McIntosh
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-17       Impact factor: 11.205

3.  Cellular STAT3 functions via PCBP2 to restrain Epstein-Barr Virus lytic activation in B lymphocytes.

Authors:  Siva Koganti; Carissa Clark; Jizu Zhi; Xiaofan Li; Emily I Chen; Sharmistha Chakrabortty; Erik R Hill; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2015-02-25       Impact factor: 5.103

4.  Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos.

Authors:  Maria Vaysberg; Olivia Hatton; Stacie L Lambert; Andrew L Snow; Bonnie Wong; Sheri M Krams; Olivia M Martinez
Journal:  J Biol Chem       Date:  2008-11-05       Impact factor: 5.157

Review 5.  Proof for EBV's sustaining role in Burkitt's lymphomas.

Authors:  David Vereide; Bill Sugden
Journal:  Semin Cancer Biol       Date:  2009-07-21       Impact factor: 15.707

6.  Activation of the JAK/STAT pathway in Epstein Barr virus+-associated posttransplant lymphoproliferative disease: role of interferon-gamma.

Authors:  M Vaysberg; S L Lambert; S M Krams; O M Martinez
Journal:  Am J Transplant       Date:  2009-07-28       Impact factor: 8.086

Review 7.  STAT3 as a target for inducing apoptosis in solid and hematological tumors.

Authors:  Khandaker Al Zaid Siddiquee; James Turkson
Journal:  Cell Res       Date:  2008-02       Impact factor: 25.617

8.  Epstein-Barr virus regulates STAT1 through latent membrane protein 1.

Authors:  Ciarán Richardson; Ceri Fielding; Martin Rowe; Paul Brennan
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  KRAB-ZFP Repressors Enforce Quiescence of Oncogenic Human Herpesviruses.

Authors:  Xiaofan Li; Eric M Burton; Siva Koganti; Jizu Zhi; Francis Doyle; Scott A Tenenbaum; Biljana Horn; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

Review 10.  Tofacitinab in renal transplantation.

Authors:  Martin S Zand
Journal:  Transplant Rev (Orlando)       Date:  2013-07       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.